Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15943729 | 0.87 | ALDH1A1 (0.47) | ALDH1A1LMNACXCL8AKR1B1PTGS1 | |
| SCHEMBL12132313 | 0.85 | ALDH1A1 (0.52) | ALDH1A1LMNASRD5A2KMT2ASMN1; SMN2 | |
| SCHEMBL7678571 | 0.85 | SRD5A2 (0.46) | ALDH1A1AKR1B1SRD5A2KMT2AHPGD | |
| SCHEMBL7676938 | 0.84 | MAPT (0.52) | ALDH1A1LMNASRD5A2KMT2AHPGD | |
| SCHEMBL7678834 | 0.84 | HPGD (0.48) | PTGS2SRD5A2KMT2ASMN1; SMN2HPGD | |
| SCHEMBL7674517 | 0.84 | LTA4H (0.43) | ALDH1A1SRD5A2HPGDHSD17B10RAB9A | |
| SCHEMBL3997292 | 0.83 | ALDH1A1 (0.43) | ALDH1A1LMNASRD5A2KMT2AAKR1C3 | |
| SCHEMBL8729528 | 0.83 | LMNA (0.47) | LMNAPTGS1SRD5A2KMT2ASMN1; SMN2 | |
| SCHEMBL7801625 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNACXCL8AKR1B1PTGS1 | |
| SCHEMBL7678876 | 0.80 | HPGD (0.41) | ALDH1A1LMNAPTGS2SRD5A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113469-A1 | SUSTAINED RELEASE COMPOSITIONS USING WAX-LIKE MATERIALS | TRUIST BANK, AS ADMINISTRATIVE AGENT FOR THE SECURED PARTIES | 2021-04-22 | — | — | US | disclosed |
| US-10888521-B2 | Sustained release compositions using wax-like materials | FARNAM COMPANIES, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-9561274-B2 | Treatment and prevention of cancer with HMGB1 antagonists | UNIVERSITY OF HAWAII (US) | 2017-02-07 | — | — | US | disclosed |
| US-20140127134-A1 | TREATMENT AND PREVENTION OF CANCER WITH HMGB1 ANTAGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-08 | — | — | US | disclosed |
| US-20130089608-A1 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs | FARNAM COMPANIES, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012170742-A2 | TREATMENT AND PREVENTION OF CANCER WITH HMGB1 ANTAGONISTS | UNIVERSITY OF HAWAII (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8221792-B2 | Sustained release pharmaceutical compositions for highly water soluble drugs | FARNAM COMPANIES, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110118243-A1 | ANTI-INFLAMMATORY DRUG DELIVERY SYSTEM | CHAMBERS LYNN | 2011-05-19 | — | — | US | disclosed |
| EP-2144599-B1 | SUSTAINED RELEASE PELLETS COMPRISING WAX-LIKE MATERIAL | FARNAM CO INC (US) | 2010-08-04 | — | — | EP | disclosed |
| EP-2144599-A2 | SUSTAINED RELEASE PELLETS COMPRISING WAX-LIKE MATERIAL | Farnam Companies, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0923546-A1 | ACYLPYRROLDICARBOXYLIC ACIDS AND ACYLINDOLDICARBOXYLIC ACIDS AND THEIR DERIVATIVES AND INHIBITORS OF THE CYTOSOLIC PHOSPHOLIPASE A2 | Merckle GmbH (DE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998005637-A1 | ACYLPYRROLDICARBOXYLIC ACIDS AND ACYLINDOLDICARBOXYLIC ACIDS AND THEIR DERIVATIVES AND INHIBITORS OF THE CYTOSOLIC PHOSPHOLIPASE A¿2? | MERCKLE GMBH (DE) | 1998-02-12 | — | — | WO | disclosed |
| US-5516803-A | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug | MCNEILAB, INC. (US) | 1996-05-14 | — | — | US | disclosed |
| WO-1995013266-A1 | ACYLPYRROLE-ALKANOIC ACIDS AND INDOLE-2-ALKANOIC ACIDS PLUS THEIR DERIVATIVES FOR USE AS INHIBITORS OF PHOSPHOLIPASE A¿2? | MERCKLE GMBH CHEM.-PHARM. FABRIK (DE) | 1995-05-18 | — | — | WO | disclosed |
| EP-0546676-A1 | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug | MCNEILAB, INC. (US) | 1993-06-16 | — | — | EP | disclosed |
| CN-1073095-A | The compositions that contains a kind of tramadol composition and a kind of nonsteroidal anti-inflammatory drug | MCNEILAB INC (US) | 1993-06-16 | — | — | CN | disclosed |
| US-4599359-A | POTENTIATION | Cooper, Stephen A. (US) | 1986-07-08 | — | — | US | disclosed |
| WO-1984002273-A1 | ANALGESIC COMBINATIONS | SANDOZ AG (CH) | 1984-06-21 | — | — | WO | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089608-A1 | Sustained Release Pharmaceutical Compositions for Highly Water Soluble Drugs | ABCG2, ABCB11, SLC7A5 | ALDH1A1 2821/4885LMNA 3523/4885CXCL8 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.